Alexander Seifalian, UCL’s Persian Scapegoat

Alexander Seifalian, UCL’s Persian Scapegoat

The London university UCL has now completed the investigation into the affair around their past honorary professor and now disgraced thoracic surgeon Paolo Macchiarini and the trachea transplants. Subject of the investigation were: the two plastic tracheas UCL produced (one sent to Karolinska Institutet and implanted in patient Andemariam Beyene in Stockholm, another used by UCL laryngologist Martin Birchall to treat Keziah Shorten, who previously received a cadaveric trachea from Macchiarini as requested by UCL) as well as four more cadaveric trachea transplants, namely the very first such intervention organised by Macchiarini and Birchall in Barcelona in 2008, on patient Claudia Castillo, as well as the three trachea transplants which took place under UCL oversight in London, on paediatric patients Ciaran Lynch, Shauna Davison and a 3-year old child who was transplanted just in May 2017 at the same Great Ormond Street Hospital (GOSH). The offhand revelations about the last transplant in this UCL report came as surprise, since it was otherwise kept secret.

No information is provided by the investigative report on how that child is doing now, in fact it seems no evidence like laboratory books, research data or patients’ medical files was ever requested and the committee relied solely on the opinions provided by the very people they were supposed to investigate: Paolo Macchiarini, Martin Birchall and GOSH paediatric surgeon and past director Martin Elliott. In fact, the report seems to become very nebulous or even creative with its use of alternative facts to avoid implicating Birchall in anything unethical at all. The only guilty party in this medical scandal is incidentally also the only non-clinician and the only non-white character in the entire Macchiarini affair: the nuclear physicist Alexander Seifalian, a Persian-Armenian and dual citizen of Iran and UK, whose lab manufactured two plastic tracheas. He was already sacked by UCL in July 2016, accused of bribery. Seifalian is also bowel cancer survivor, which did not prevent UCL of accusing him of failing to oversee the abroad clinical application of his produce just when he was receiving chemotherapy.

These are the results of UCL investigation in the nutshell:

  • All UCL-employed clinicians involved in trachea transplants, in particular UCL’s chief trachea transplanter Martin Birchall, are fully acquitted from any suspicion of misconduct or clinical wrongdoing. Even Macchiarini seems partially exonerated from the gist of the UCL report, because:
  • The maker of the two plastic tracheas, Alexander Seifalian, is to take all the UCL-related blame for the failed  transplants (as well as other plastics implants in India, Iran and Switzerland). His fault is to have manufactured these products though his UCL lab lacked GMP (Good Manufacturing Practice) certificate. Only this lack of GMP-quality seal was what apparently made plastic tracheas too dangerous to implant in humans.
  • All five cadaveric trachea transplants under the scope of investigation were considered ethically, medically and scientifically justified. Deaths of the patients were explained with new discoveries of recurrent cancer, or demands of other patients for the same hospital bed.
  • Birchall’s clinical trials with cadaveric tracheas (phase 1/2a INSPIRE, and by extension, also EU-wide phase 2 TETRA) are to go ahead as planned and to recruit patients. Same positive recommendation for Birchall’s related trial RegenVox on cadaveric larynx, decellurised and “regenerated” with same technology as tracheas.

Continue reading “Alexander Seifalian, UCL’s Persian Scapegoat”

EU commemorates dead patients of Macchiarini & Birchall with a phase 2 trachea transplant trial TETRA

EU commemorates dead patients of Macchiarini & Birchall with a phase 2 trachea transplant trial TETRA

The European Commission now took 40 days to deny my second Freedom of Information (FOI) Inquiry about the TETRA phase 2 clinical trial with cadaveric trachea transplant they are currently financing with €7 Million. This is EU’s second attempt to become world-leading manufacturer of industrial trachea transplants, after the €5mn Biotrachea led by the scandal surgeon Paolo Macchiarini was terminated mid-term. No, not because EU had any concerns for the patients, quite the opposite: he was given a clean ethics vote to go ahead. Biotrachea was terminated by the EU because the plastic tracheas Macchiarini wanted to use lacked novelty, as the documents I obtained revealed.

The TETRA trial, led by Macchiarini’s past collaborator, the UCL laryngologist Martin Birchall, was already on the brink of being terminated in the wake of the Macchiarini scandal, as EU previously indicated to me. Now, exactly the opposite happens. The trial is being prepared at full speed despite the fact that its predecessor phase 1 trial INSPIRE was suspended (because of my reporting), never recruited any of its four patients and it most likely never will. That trial is also led by Birchall (details here), it is likely that its Innovate UK funding has ran out meanwhile. EU however seems to signal that they will go ahead with phase 2 trial even if phase 1 never happens. After all, there are those 10 patients who received a cadaveric trachea transplant  (here and below) and were operated under hospital exemptions between 2008 and 2012 by Macchiarini and Birchall. At least half of these 10 are dead, the lucky survivors either had their graft removed or live with permanently installed stents to prevent their rotting airways from collapsing (INSPIRE’s and TETRA’s clinical promise is actually that the patients will never need a stent). But this disaster seems exactly the reason for EU to try it again, and on a much, much bigger scale. Probably because it will create employment.

The EU spokesperson ceased long ago answering my emails, after I declined to be instructed over the phone (strictly off-the-record) why EU’s approach to trachea transplanting is right; this is why I had to resort to FOI. The official time limit to answer my FOI inquiry from July 1st 2017 was 15 days, but the EU first pretended not to have received my postal address, then said they need more time, then said they need extra time to assemble the documents for me, and finally, the Director-General of the European Commission, Robert-Jan Smits, wrote to me on September 11th. He basically told me again to get lost and that he will never release any information (read here his past rejection of my FOI inquiry). His reasons, as before: the trachea transplant trial is a business enterprise and revealing any of its progress might endanger the financial interests of its stakeholders, and then there are privacy concerns. Exactly, Smits decided that the public must under no circumstances find out whom exactly the EU is giving this public’s money for research on humans. I am not making it up, read Smits’ letter yourself hereContinue reading “EU commemorates dead patients of Macchiarini & Birchall with a phase 2 trachea transplant trial TETRA”

The PubPeer Stars of Weizmann Institute

The PubPeer Stars of Weizmann Institute

Journals generally avoid acting on data manipulation, unless forced to by investigations from universities and research institutions. The Lancet‘s current stance on Macchiarini (and previously Wakefield) affair is probably the most dangerous example. Practically at every single research integrity conference (which are usually organised by major publishers like Elsevier), publishing executives preach that journals should never be asked to deal with data manipulations in papers they publish,  but only respond to the final results of institutional investigations.

Actually, even there journals prefer not to retract as requested, as Science did in the case of Olivier Voinnet. On the other hand, some publishers are ready to forgive all misconduct when a unrepentant cheater offers them a new hot paper. Nature Publishing group, EMBO Press and even the publisher lobby group COPE recently protested against journals’ cheater blacklists, in connection with the data-faking plant researcher Patrice Dunoyer, a past Voinnet associate (his story here). And some journals even openly take the side of cheater scientists, while attacking PubPeer whistleblowers, as F1000 Research seemingly did, see tweet below.

Scholarly journals mostly act like grocery shops, which despite better knowledge refuse to remove contaminated foods off the shelves until manufacturer’s official recall, regardless of how many glass shards were found inside. It therefore lies in the hands of research institutions when fraud and cheating continue unabated, while research community is fooled and robbed, left alone with futile attempts to reproduce dishonest papers full of secret data manipulations. Yet this is exactly what Weizmann Institute of Science in Israel is good at:

The Art of Not Investigating

The following article lists Weizmann scientists with some serious evidence on PubPeer against the trustworthiness of their research. Before this elite institution from Rehovot, that most famous biomedical research centre in Israel, dismisses my article as anti-Semitic slander of an obscure German Nazi blogger, they should first try it with declaring me an assimilation-corrupted, self-hating diaspora Jew. Continue reading “The PubPeer Stars of Weizmann Institute”

Unpublished Macchiarini manuscript confirms 5 forgotten trachea transplant patients

Unpublished Macchiarini manuscript confirms 5 forgotten trachea transplant patients

7.09.2017 This article was slapped with an injunction by Berlin court (here), on behalf of Jungebluth. Sentences forbidden by injunction are replaced to show the legal truth. 

I have been forwarded a manuscript by the scandal surgeon Paolo Macchiarini, which was originally intended to present in detail all of his known 9 cadaveric trachea recipients (only 4 are recorded officially). The compilation follows exactly all the patients who are already listed on my site, with the small difference that the paper (allegedly rejected at Nature Communications) presents their clinical evolutions quite differently from reality. One of these now fully confirmed victims of Macchiarini’s research was his second patient from Barcelona, whom Macchiarini transplanted in secret; five were operated in Italy (including Keziah Shorten and the Czech patient MK). The manuscript also confirms that Macchiarini’s acolyte Philipp Jungebluth [is an angel of innocence and never did anything bad in his life. Every patient ever treated by him is in fact eternally grateful]. The German doctor is currently suing me in court for alleged libel, insisting that all these patient deaths and his proven research misconduct in Sweden would never ever disqualify him from developing trachea transplants and training as thorax surgeon at the University Clinic Heidelberg, where he however doesn’t work anymore.

The first author of this lost and now found unpublished paper is Johannes Haag, Macchiarini’s other acolyte and former MD student from Hannover Medical School (MHH) in Germany. Haag is apparently still employed at the Thoraxklinik at the University of Heidelberg, where Jungebluth used to be. The manuscript, which was supposed to be Haag’s big paper, was written to deal with the fact that too many of Macchiarini’s cadaveric trachea recipients died or developed very severe complications. To this end, the team hatched an idea to do “reverse translational experiments“, where rat experiments would follow those on 9 humans, prove that the cadaveric trachea technology works in principle and it was the human patients who were making problems. This notion was to be supported also by their earlier pig study Go et al, Biomaterials 2010, where Macchiarini and Jungebluth claim, without a shred of evidence, that the large animal testing was performed before the first patient, Claudia Castillo, received a cadaveric trachea in 2008 (details here, here and here). Update 7.09.2017: Go et al  2010 paper was criticised on PubPeer for its heavy scientific and technical deficits.

Continue reading “Unpublished Macchiarini manuscript confirms 5 forgotten trachea transplant patients”

German Leibniz institute director Karl Lenhard Rudolph guilty of misconduct

German Leibniz institute director Karl Lenhard Rudolph guilty of misconduct

A major misconduct finding hits German life sciences. Karl Lenhard Rudolph, stem cell and ageing researcher, director of the Fritz-Lippmann-Institute (FLI) of the Leibniz Society, was found guilty of research misconduct by an investigation of the Leibniz Society, in a decision published on June 15th. 11 papers in total were investigated, going back as far as 2001. One paper is to be retracted, seven Errata were requested. The investigation confirmed duplications of image parts, inappropriate splicing, rigged loading controls etc. No original data or lab books were available.

Just in Mai 2016, Rudolph’s FLI was raided by the police “on  suspected breaches of the animal welfare and drug law, as well as embezzlement” . All animal experimenting was stopped till present day, according to Radio Jena, other sources quoted Rudolph in May 2017 that mouse experiments were approved again, though the police investigation continued. Rudolph also admitted that his own lab was also part of the problem and that 13,000 mice were killed unnecessarily. Was Leibniz Society’s recent tough and public disciplinary action upon FLI director Rudolph the consequence?

The translated report on Rudolph’s research misconduct (my own version) is published below, the German original is here. I have not yet determined which publications from Rudolph lab were investigated, but 5 Rudolph papers were previously flagged on PubPeer. His institute, located in the Eastern German town of Jena, is now banned from Leibniz funding for 3 years, FLI now must report back to the Leibniz Executive Board until November 1st 2017 on the improvements regarding data documentation, quality control as well as tutoring and supervision of employees. Continue reading “German Leibniz institute director Karl Lenhard Rudolph guilty of misconduct”

Macchiarini’s trachea transplant patients: the full list

Macchiarini’s trachea transplant patients: the full list

This article lists all known (including those not officially declared) patients of the scandal surgeon Paolo Macchiarini, who received from him a cadaveric or plastic trachea. All these grafts were “regenerated” with bone marrow and epithelial cells, in some cases a bioreactor was used to incubate cells on the trachea carcass, in some cases a “bionic” method was applied,  where cells were brought straight into the open patient, together with growth factors like EPO. Not all patients are named in my list, though names of all are available, certainly at the hospitals where they were treated. One of my sources is a patients list from the Careggi Hospital in Florence, Italy, which the Corriere Fiorentino journalist Alessio Gaggioli sent me.  Some of the patients I already described in an earlier article.

This now is a full list, and it will be updated whenever I receive any new evidence. All Macchiarini trachea transplant patients are listed in the chronological order of their operation. The 2003 operated patient (story here), who received from Macchiarini (together with Heike and Thorsten Walles) a small “regenerated” tracheal patch of pig intestine, is not included here, as it was not a trachea transplant as such. There is a total of 17 patients, at least 11 are dead, the rest, if alive, were left mutilated.

Continue reading “Macchiarini’s trachea transplant patients: the full list”

Keziah’s deadly trachea transplant: UCL hospital’s secret

Keziah’s deadly trachea transplant: UCL hospital’s secret

Keziah Shorten was a 19-year old teenager from England and officially Paolo Macchiarini 3rd patient receiving a cadaveric trachea transplant. She suffered from a slow growing form of cancer and received a cadaveric trachea transplant from Macchiarini at the Careggi hospital in Florence. After life-threatening complications ensued, her second transplant, a plastic trachea made and implanted at UCL and its UCL hospital (UCLH) in London, failed also. Keziah died one and a half years after her first operation. With new evidence provided to me by a source close to the patient, I present here a version of Keziah’s story which is very much different from the official one. This makes UCL and UCLH at least in part responsible for her death, from the very beginning. It was their decision to treat Keziah with the first cadaveric transplant, which sealed her fate.  Next to the UCL honorary professor Macchiarini himself, the British doctors, who according to my source promised Keziah a complete cure and initiated this transplant, were UCL professors and surgeons Martin Birchall and Paul O’Flynn. Keziah was even supposed to be operated at UCLH, but once Macchiarini got an ethics permit in Italy, she was moved there. O’Flynn followed her and joined Macchiarini in the transplant operation. Afterwards, it was an ongoing catastrophe which was exacerbated by an apparent botched intervention at UCL Hospital. Death seemed a relief after terrible suffering imposed on Keziah by fame-seeking doctors worshipping their own magic of regenerative medicine. Continue reading “Keziah’s deadly trachea transplant: UCL hospital’s secret”